Skip to main content

Table 1 Published or ongoing trials of immunotherapy in EC:

From: Immunotherapy in endometrial cancer: rationale, practice and perspectives

Mechanism of action NCI identifie Agents Phase Setting/cancer type Patient number Subtype contribution Outcomes Status
anti-PD-1
antibody
NCT01876511 Pembrolizumab II Advanced MMR-deficient Cancers including EC Total:86, EC:15 all MMR-d ORR, DCR, PR, SD, PD published
NCT02054806 Pembrolizumab Ib PD-L1 positive Advanced EC 24 POLE:1, MSI-high:1, MSS:17, Not evaluable:5 ORR, median PFS, median OS, PR, SD, PD published
NCT02628067 Pembrolizumab II Noncolorectal MMR-d cancers including EC Total:233, EC:49 all MMR-d CR, PR, ORR, median PFS, median OS, median DOR published
NCT02465060 Nivolumab II Noncolorectal MMR-d cancers including EC Total:42, EC:13 all MMR-d ORR, CR, PR, SD, PD, median PFS published
Abti-PD-1 antibody+
Antiangiogenic therapy
NCT03015129 Pembrolizumab+
Lenvatinib
II rEC 108 MSI:11,MSS:94 ORR, PFS, OS, DOR published
anti-PD-L1 antibody NCT01375842 Atezolizumab Ia rEC 15 MSI-H:1, MSS:7, unknown for MMR status:7 ORR, PFS,OS published
NCT02912572 Avelumab II rEC 33 MSS:16, MSI:17 OR, PFS6 published
ACTRN12617000106336 Durvalumab II advanced EC 71 MSI:36, MSS:35 OTR, PFS, OS published
anti-PD-L1 antibody+
anti-CTLA-4
NCT03015129 Durvalumab and Tremelimumab versus Durvalumab Monotherapy II rEC and Endometrial Carcinosarcoma Total:56, EC:41 MSI:5, MSS:48, unknown:3 ORR, median DOR, PFS, PFS rate at 24 wks published
tumor antigen loaded DC cancer vaccine EudraCT 2009-016868-37 WT1mRNA-electroporated mature DCs (DCm-WT1-
RNA)
I/II Uterine Tumor Total:6, serous EC:3 NA PFS, OS, Oncologic outcome
(CT Scan,
CA125),
Immune Response
(WT1-specific T-cells, NK cells)
published
peptide cancer vaccine+
anti-tumor cytokine
NCT01580696 E39 peptide waccine+
GM-CSF
I/IIa Ovarian and EC Total:51, EC:9 NA DFS published
Chimeric peptide cancer vaccine BB-IND-9803 B-cell epitopes of HER2-Th (MVF) epitope chimeric peptide vaccine I Metastatic and/or Recurrent Solid Tumors including EC Total:24, EC:1 NA antibody response, PR, SD published
nucleic acid-based cancer vaccine+
anti-PD-1 antibody
NCT03313778 mRNA-4157 vaccine+
Pembrolizumab
I Resectable/Unresectable Solid Tumors including EC Total:33, EC:1 MSI PR, SD, PD, neoantigen-specific T cell response published
ACT+
hyperthermia+
anti-PD-1 antibody/
chemotherapy
NCT03757858 Autologous Adoptive T cell Transfer+
Hyperthermia+
Pembrolizumab/
Chemotherapy
I Advanced Solid Tumors including EC Total:33, EC:5 NA ORR, DCR, Clinical Response
(CR, PR, SD, PD)
published
anti-PD-1 antibody NCT02628067 Pembrolizumab II Advanced Solid Tumors including EC NA NA ORR Recruiting
NCT02630823 Pembrolizumab I Surgically Resectable EC NA NA AEs Active, not recruiting
NCT02728830 Pembrolizumab I Gynecologic Cancers including EC NA NA Fold change in tumor Immune Infiltrates Active, not recruiting
NCT02899793 Pembrolizumab II Advanced, Recurrent or Metastatic EC NA POLE,MSI ORR,AEs Recruiting
NCT03241745 Nivolumab II Metastatic or Recurrent Uterine Cancer NA all dMMR(EC) PFS Recruiting
NCT03568539 IBI308 Ib Advanced or Metastatic Solid Tumors including EC NA NA Overall Response Rate,CR,PR Active, not recruiting
anti-PD-1 antibody+
Surgery
NCT03694834 Pembrolizumab+
Hysterectomy+
Surgical staging
I Early Stage, High Grade Obesity-driven EC NA NA TIL Suspended
anti-PD-1 antibody+
Surgery+
Chemotherapy
NCT03932409 Pembrolizumab+
Vaginal Cuff Brachytherapy+
Paclitaxel+
Carboplatin
Ib High Intermediate Risk EC NA NA Proportion of patients completing three cycles Not yet recruiting
anti-PD-1 antibody+
Chemotherapy
NCT02549209 Pembrolizumab+\Carboplatin+
Paclitaxel
II Advanced, Recurrent
or Metastatic EC
NA NA ORR Recruiting
NCT03276013 Pembrolizumab+
Doxorubicin
II Advanced, Recurrent
or Metastatic EC
NA NA PFS Active, not recruiting
NCT03981796 Dostarlimab+
Carboplatin-
Paclitaxel
III Advanced, Recurrent
or Metastatic EC
NA will
do MMR evaluation
PFS Recruiting
NCT03914612 Pembrolizumab+
Paclitaxel+
Carboplatin
III Stage III/IV
or Recurrent EC
NA will
do MMR evaluation
PFS Recruiting
anti-PD-1 antibody+Radiotherapy NCT04214067 Pembrolizumab+
Radiation therapy
III High Intermediate Risk Endometrioid EC NA all dMMR 3 year recurrence
-free survival
Not yet recruiting
NCT03955978 Dostarlimab+
Standard of Care Definitive Radiation
I Inoperable EC NA NA Safety and tolerability Recruiting
anti-PD-1 antibody+PARP inhibitor NCT03016338 Dostarlimab+
Niraparib
II Advanced,Recurrent or Metastatic EC NA NA Clinical benefit rate Recruiting
NCT03572478 Nivolumab+
Rucaparib
Ib/IIa Advanced or Recurrent EC and Metastatic Castrate-Resistant Prostate Cancer NA NA DLT rate Recruiting
anti-PD-1 antibody+
Antiangiogenic therapy
NCT04197219 Pembrolizumab+
Axitinib
II Advanced, Recurrent or Metastatic EC NA all dMMR ORR,CR,
PR
Not yet recruiting
NCT02501096 Pembrolizumab+
Lenvatinib
Ib/II metastatic Solid Tumors including EC NA NA MTD,ORR,DLT Active, not recruiting
NCT03367741 Nivolumab+
Cabozantinib
II Advanced, Recurrent or Metastatic EC NA NA PFS Suspended
NCT03517449 Pembrolizumab+
Lenvatinib
III Advanced, Recurrent or Metastatic EC NA will do MMR evaluation PFS,OS Active, not recruiting
NCT03884101 Pembrolizumab+
Lenvatinib
III Advanced, Recurrent or Metastatic EC NA will do MMR evaluation PFS,OS Recruiting
NCT04157491 anti-PD-1 antibody+
Anlotinib
II Advanced, Recurrent or Metastatic EC NA NA ORR,CR,
PR
Recruiting
anti-PD-1 antibody+IDO inhibitor NCT02178722 Pembrolizumab+
Epacadostat (INCB024360)
I/II Cancers including EC NA NA TEAEs, ORR Active, not recruiting
NCT04106414 Nivolumab+
BMS-986205
II Recurrent or Persistent EC or Endometrial Carcinosarcoma NA will do MMR evaluation Best overall response rate Recruiting
anti-PD-1 antibody+
anti-CTLA-4 antibody
NCT02982486 Nivolumab+
Ipilimumab
II Nonresectable or Metastatic EC and Sarcoma NA all dMMR CR,PR Not yet recruiting
anti-PD-1 antibody+
4-1BB antibody
NCT03917381 GEN1046 I/II Malignant Solid Tumors including EC NA NA DLT,AEs,
Safety laboratory parameters
Recruiting
anti-PD-1 antibody+
CFTR inhibitor
NCT04014530 Pembrolizumab+
Ataluren
I/II Metastatic EC and Colorectal Adenocarcinoma NA all dMMR(EC) ORR Recruiting
anti-PD-1 antibody+
Dual Adenosine Receptor
(A2aR/A2bR) Antagonist
NCT03629756 Zimberelimab (AB122)+
AB928
I Advanced Solid Tumors including EC NA NA DLTs,AEs Recruiting
anti-PD-1 antibody+
FRα ADC
NCT03835819 Pembrolizumab+
Mirvetuximab Soravtansine (IMGN853)
II Advanced, Recurrent or Metastatic EC NA all MSS ORR, PFS Recruiting
anti-PD-1 antibody+
Hormone
NCT04046185 Toripalimab+
Progesterone
I Early EC
(preserve fertility)
NA NA Pathologic complete
/patrial remission rate
Not yet recruiting
anti-PD-1 antibody+IAP NCT04122625 Nivolumab+
Mimetic
Debio 1143
Ib/II Solid Tumors including EC, progressed during/immediately after anti-PD-1/PD-L1 treatment NA known MMR status ORR Recruiting
anti-PD-1 antibody+
Immune Modulatory Cocktail+
Radiotherapy+
Food supplement
NCT03192059 Pembrolizumab+
Immune Modulatory Cocktail
(Vitamin D+
Lansoprazole Teva+
Cyclophosphamide+Aspirine,)
+Radiotherapy
+Curcumin
II Refractory or Recurrent EC, CC, Uterine sarcoma NA NA ORR Recruiting
anti-PD-1 antibody+
multi-targeted RTK inhibitor
NCT03827837 Camrelizumab+
Famitinib
II Advanced RCC/UC/CC/EC and Recurrent OC NA NA Overall response rate Recruiting
anti-PD-1 antibody+
PVRIG antibody
NCT03667716 COM701 monotherapy or COM701+
Nivolumab
Ia/b Advanced or Metastatic Solid Tumors including EC NA NA AEs ,DLTs,MTD, RDFE Recruiting
anti-PD-L1 antibody NCT02725489 Durvalumab+Vigil II Advanced Women's Cancers including EC NA NA AEs Active, not recruiting
NCT03212404 Cosibelimab I Advanced
or Metastatic Solid Tumors including EC
NA NA DLT,AEs,ORR Recruiting
anti-PD-L1 antibody+
Chemotherapy
NCT02914470 Atezolizumab+
Carbplatin+
Cyclophophamide
Ib Advanced Gynaecologic Cancer including EC,BC NA NA Toxicity, Incidence of toxicity,AEs Active, not recruiting
NCT03503786 Avelumab+
Carboplatin+
Paclitaxel
II Advanced, Recurrent
or Metastatic EC
NA NA PFS Not yet recruiting
NCT03603184 Atezolizumab+
Paclitaxel+
Carboplatin
III Advanced, Recurrent
or Metastatic EC
NA Will do MMR evaluation OS,PFS Recruiting
anti-PD-L1 antibody+
Antiangiogenic therapy
NCT03170960 Atezolizumab+
Cabozantinib
Ib Advanced or Metastatic Solid Tumors including EC NA NA MTD/RD,ORR Recruiting
NCT03526432 Atezolizumab+ Bevacizumab II Advanced, Recurrent or Metastatic EC NA will do MMR evaluation Number of patients who experience CR or PR Recruiting
anti-PD-L1 antibody+PARP inhibitor NCT02912572 Avelumab/
Avelumab+
Talazoparib
II Advanced, Recurrent or Metastatic EC NA POLE,MSI,MSS PFS Recruiting
NCT03101280 Atezolizumab+
Rucaparib
Ib Advanced Gynecologic Cancers inclunding EC, TNBC NA NA AEs,DLTs,RP2D,Number of Dose Modifications due to AEs Active, not recruiting
NCT03951415 Durvalumab+
Olaparib
II Advanced, Recurrent or Metastatic EC NA NA PFS Recruiting
anti-PD-L1 antibody+
Chemotherapy+
PARP inhibitor
NCT04269200 Durvalumab+
Carboplatin+
Paclitaxel+
Olaparib
III Advanced, Recurrent or Metastatic EC NA will do MMR evaluation PFS Not yet recruiting
anti-PD-L1 antibody+
Antiangiogenic therapy+
PARP inhibitor
NCT03694262 Atezolizumab+
Bevacizumab+
Rucaparib
II Advanced, Recurrent or Metastatic EC NA will do MMR evaluation Overall Response Rate Recruiting
anti-PD-L1 antibody+
IDO inhibitor
NCT02471846 Atezolizumab+
GDC-0919
Ib Advanced or Metastatic Solid Tumors including EC NA NA DLTs,AEs Completed
anti-PD-L1 antibody+
anti-CTLA-4 antibody
NCT03015129 Durvalumab+
Tremelimumab
II Persistent or Recurrent EC and Endometrial Carcinosarcoma NA NA Overall Response Rate Recruiting
anti-PD-L1 antibody+
anti-CTLA-4 antibody+
Radiotherapy
NCT03277482 Durvalumab+
Tremelimumab+
Radiotherapy
I Recurrent Gynecologic Cancer including EC NA NA MTD Recruiting
anti-PD-L1 antibody+
anti-5T4 antibody-superantigen fusion protein
NCT03983954 Durvalumab+
Naptumomab
Ib/II Advanced or Metastatic Solid Tumors including EC NA NA AEs,MTD,RP2D Recruiting
Dual Blockade
of PD-1 and CTLA-4
NCT03517488 XmAb20717 I Advanced Solid Tumors including EC NA all dMMR(EC) AEs Recruiting
anti-B7-H4 antibody NCT03514121 FPA150 Ia/b Advanced or Metastatic Solid Tumors including EC NA NA MTD,RD,AEs Active, not recruiting
anti-LAG-3 antibody NCT03538028 INCAGN02385 I Advanced or Metastatic Solid Tumors including EC NA all dMMR(EC) TEAEs Recruiting
  1. CR Complete Response, DCR Disease Control Rate, DOR Duration of Response, OR Objective Response, ORR Objective Response Rate, OS Overall Survival, OTR Objective Tumour Response, PD Progressive Disease, PFS Progression-Free Survival, PFS6 Progression-Free Survival at 6 months, PR Partial Response, rEC advanced or recurrent EC, SD Stable Disease, ADC Antibody-drug conjugates, AEs Adverse Events, BC Breast Cancer, CC Cervical Cancer, DLTs Dose-Limiting Toxicities, MTD Maximum Tolerated Dose, OC Ovarian Cancer, RCC Renal Cell Carcinoma, RD Recommended Dose, RDFE Recommended Dose for Expansion, RP2D Recommended Phase II Dose, TEAEs Treatment-Emergent Adverse Events, TIL Tumor Infiltrating Lymphocytes, TNBC Triple-Negative Breast Cancer, UC Urothelial Carcinoma.